Business · 09/02/2016
FDA Releases Guidance on Premarket Notifications for Lamotrigine and Zonisamide Assays
The FDA has made available a new guidance document outlining the necessary information for premarket notifications related to zonisamide and lamotrigine assays, aimed at both industry and FDA staff.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →